In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Audited Standalone & Consolidated Financial results for the Quarter & Year Ended ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gennex Laboratories reported strong revenue growth with consolidated total income of Rs 18,098.67 Lacs for FY2026, up 22% from Rs 14,833.31 Lacs in FY2025. Standalone revenue from operations grew 26.7% to Rs 11,985.67 Lacs. Consolidated net profit increased 15.7% to Rs 2,097.88 Lacs, while standalone net profit rose 14.9% to Rs 1,612.81 Lacs. However, the auditors issued a Qualified Opinion citing unconfirmed balances of current assets, liabilities, and other items with unascertained impact. The company is implementing transaction traceability software to address this. Cash flow from operations turned significantly negative at Rs 6,365.39 Lacs (consolidated) and Rs 4,018.28 Lacs (standalone), indicating working capital stress despite profitability.
The qualified audit opinion raises concerns about balance sheet accuracy and internal controls, which could weigh on investor sentiment. Strong revenue growth is offset by negative operating cash flow and rising receivables, suggesting potential liquidity challenges ahead.